Financial Daily from THE HINDU group of publications
Wednesday, Apr 19, 2006
Financial Daily from THE HINDU group of publications Wednesday, Apr 19, 2006 |
|
|
|
|
|
|
|
Corporate
-
Standards & Benchmarks Ethypharm may offer full solutions from India P.T.Jyothi Datta
NDDS Ethypharm specialises in developing novel delivery systems for medicines. Novel drug delivery systems (NDDS) is a $75-billion market or about 15 per cent of the global pharma market. In India, NDDS is about four per cent of the local pharma market.
Mumbai , April 18 Ethypharm India hopes to be able to work end-to-end on its drug delivery technologies, after its manufacturing facility in India gets a European regulatory certification. Scaling-up the plant to the EUGMP (European Union Good Manufacturing Practices) norms would help Ethypharm develop a technology from concept to commercial manufacturing, Mr Ajey Kumar, Chief Executive Officer, Ethypharm LL India, told Business Line. The company hopes to apply for the EU certification of its plant at Ambernath, Maharashtra, in about six months. At present, work that comes to India is sent back to France at different stages of development.
EU certification
Getting EUGMP will help Ethypharm India supplement the work of its French-parent, besides supporting the company's client-base, thus keeping costs in check, he said.
Investment plan
It will put the manufacturing facilities in different areas to optimal use, as clients can be supported depending on their requirements, he added. A wholly-owned subsidiary of the France-based Ethypharm S.A., the Indian outfit had drawn up a $3 million investment plan for its local operations late last year. Part of this investment was to go towards the scaling up of its plant at Ambernath, besides upgrading its research centre here. Ethypharm specializes in developing novel delivery systems for medicines, a market that is set to grow in India and China. Novel drug delivery systems (NDDS) is a $75 billion market or about 15 per cent of the global pharma market. In India, NDDS is about four per cent of the local pharma market. Ehtypharm expects the NDDS market to grow as the pharmaceutical market develops and Mr Kumar said that his company is set to double its revenues in two to three years. No financials were divulged. Besides developing innovative technologies for drug delivery and licensing it out to pharma companies, Ethypharm also works in tandem with pharma companies to help develop a technology to meet the latter's requirement. Revenues flow in from the licensing deals and royalties as different milestones are met on these deals. This is in addition to increased manufacturing bringing in more revenues, he explained. Ethypharm's clientele includes several big drug companies in the country and overseas.
More Stories on : Standards & Benchmarks | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|